Skip to main content
Erschienen in: Molecular Diagnosis & Therapy 1/2009

01.03.2009 | Original Research Article

Development and Validation of a High-Throughput Screening Method for Two Polymorphisms in the Serotonin Transporter Gene

verfasst von: Mr Moritz Eidens, Alexander Weise, Stefan Prause, Norbert Dahmen, Annette Wunsch, Mathias Max Weber, Thomas Forst, Andreas Pfützner

Erschienen in: Molecular Diagnosis & Therapy | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Background and Aim: The human serotonin (5-hydroxytryptamine) transporter, encoded by the SLC6A4 gene on chromosome 17q11.1–q12, is the cellular reuptake site for serotonin and a site of action for several drugs with central nervous system effects, including both therapeutic agents (e.g. antidepressants) and drugs of abuse (e.g. cocaine). It is known that the serotonin transporter plays an important role in the metabolic cycle of a broad range of antidepressants, antipsychotics, anxiolytics, antiemetics, and antimigraine drugs. The identification and characterization of variations that increase the response to common medications is a hallenging and increasingly important task with regard to prediction of drug response. Therefore, the aim of this study was to establish a high-throughput single nucleotide polymorphism (SNP) screening method for two polymorphisms in the serotonin transporter gene, focusing on the SLC6A4 variations rs140701 and rs2066713.
Methods: We developed a classical restriction fragment length polymorphism (RFLP) PCR protocol as a reference, followed by a new protocol established for the LightCycler® real-time PCR method. To validate the method, the allele frequencies in 169 individuals (112 women, 57 men) were determined and compared with published data. The population was divided into two groups: one group comprised 87 individuals with various mental disorders and the other consisted of 82 healthy persons.
Results: No difference was found in the prevalence of the two SNPs between the two populations. Subsequently, the determined allele frequencies were compared with previously published data. We found that 68% of the whole study population (groups I and II) carried a mutated allele of the rs140701 variation. With regard to the rs2066713 polymorphism, we found an allele frequency of 61% in the population. Both results are consistent with published data.
Conclusion: The developed protocol for RT-PCR analysis of both variations turned out to be reliable and economical, and thus suitable for routine laboratory use.
Literatur
1.
Zurück zum Zitat Ramamoorthy S, Bauman AL, Moore K, et al. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Nat Acad Sci 1993; 90: 2542–6PubMedCrossRef Ramamoorthy S, Bauman AL, Moore K, et al. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Nat Acad Sci 1993; 90: 2542–6PubMedCrossRef
2.
Zurück zum Zitat Gelernter J, Pakstis AJ, Kidd KK. Linkage mapping of serotonin transporter protein gene (SLC6A4) on chromosome 17. Hum Genet 1995; 95: 677–80PubMedCrossRef Gelernter J, Pakstis AJ, Kidd KK. Linkage mapping of serotonin transporter protein gene (SLC6A4) on chromosome 17. Hum Genet 1995; 95: 677–80PubMedCrossRef
3.
Zurück zum Zitat Holmes C, Arranz M, Collier D, et al. Depression in Alzheimer’s disease: the effect of serotonin receptor gene variation. Am J Med Genet 2003; 119B(1): 40–3PubMedCrossRef Holmes C, Arranz M, Collier D, et al. Depression in Alzheimer’s disease: the effect of serotonin receptor gene variation. Am J Med Genet 2003; 119B(1): 40–3PubMedCrossRef
4.
Zurück zum Zitat Lesch KP, Balling U, Gross J, et al. Organisation of the human serotonin transporter gene. J Neural Trans 1994; 95: 157–62CrossRef Lesch KP, Balling U, Gross J, et al. Organisation of the human serotonin transporter gene. J Neural Trans 1994; 95: 157–62CrossRef
5.
Zurück zum Zitat Strug LJ, Suresh R, Fyer AJ, et al. Panic disorder is associated with the serotonin transporter gene (SLC6A4) but not the promoter region (5-HTTLPR). Mol Psychiatry. Epub 2008 Jul 29 Strug LJ, Suresh R, Fyer AJ, et al. Panic disorder is associated with the serotonin transporter gene (SLC6A4) but not the promoter region (5-HTTLPR). Mol Psychiatry. Epub 2008 Jul 29
6.
Zurück zum Zitat Søeby K, Larsen SA, Olsen L, et al. Serotonin transporter: evolution and impact of polymorphic transcriptional regulation. Am J Med Genet B Neuropsychiatr Genet 2005; 5: 53–7 Søeby K, Larsen SA, Olsen L, et al. Serotonin transporter: evolution and impact of polymorphic transcriptional regulation. Am J Med Genet B Neuropsychiatr Genet 2005; 5: 53–7
7.
Zurück zum Zitat Weiss LA, Abney M, Cook EH, et al. Sex-specific genetic architecture of whole blood serotonin levels. Am J Hum Genet 2005; 76: 33–41PubMedCrossRef Weiss LA, Abney M, Cook EH, et al. Sex-specific genetic architecture of whole blood serotonin levels. Am J Hum Genet 2005; 76: 33–41PubMedCrossRef
8.
Zurück zum Zitat Weiss LA, Abney M, Parry R. Variation in ITGB3 has sex-specific associations with plasma lipoprotein (a) and whole blood serotonin levels in a population-based sample. Hum Genet 2005; 117: 81–7PubMedCrossRef Weiss LA, Abney M, Parry R. Variation in ITGB3 has sex-specific associations with plasma lipoprotein (a) and whole blood serotonin levels in a population-based sample. Hum Genet 2005; 117: 81–7PubMedCrossRef
9.
Zurück zum Zitat Chung Y, Lee SY, Elston RC, et al. Odds ratio based multifactor-dimensionality reduction method for detecting gene gene interactions. Bioinformatics 2007; 23(1): 71–6PubMedCrossRef Chung Y, Lee SY, Elston RC, et al. Odds ratio based multifactor-dimensionality reduction method for detecting gene gene interactions. Bioinformatics 2007; 23(1): 71–6PubMedCrossRef
10.
Zurück zum Zitat Stein MB, Seedat S, Gelernter J, et al. Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder. Psychopharmacology (Berl) 2006 Jul; 187(1): 68–72CrossRef Stein MB, Seedat S, Gelernter J, et al. Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder. Psychopharmacology (Berl) 2006 Jul; 187(1): 68–72CrossRef
Metadaten
Titel
Development and Validation of a High-Throughput Screening Method for Two Polymorphisms in the Serotonin Transporter Gene
verfasst von
Mr Moritz Eidens
Alexander Weise
Stefan Prause
Norbert Dahmen
Annette Wunsch
Mathias Max Weber
Thomas Forst
Andreas Pfützner
Publikationsdatum
01.03.2009
Verlag
Springer International Publishing
Erschienen in
Molecular Diagnosis & Therapy / Ausgabe 1/2009
Print ISSN: 1177-1062
Elektronische ISSN: 1179-2000
DOI
https://doi.org/10.1007/BF03256312

Weitere Artikel der Ausgabe 1/2009

Molecular Diagnosis & Therapy 1/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.